Title: Saxagliptin: a novel antiparkinsonian approach.
Journal: Neuropharmacology 20150201
Title: Saxagliptin overview: special focus on safety and adverse effects.
Journal: Expert opinion on drug safety 20130101
Title: Development of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.
Journal: Biomedical chromatography : BMC 20121201
Title: Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
Journal: Pharmacoepidemiology and drug safety 20121101
Title: Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Journal: Journal of clinical pharmacology 20121001
Title: Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20121001
Title: Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
Journal: Current medical research and opinion 20121001
Title: Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
Journal: Bioanalysis 20120801
Title: Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
Journal: Primary care diabetes 20120701
Title: Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120701
Title: Pharmacokinetic study of saxagliptin in healthy Chinese subjects.
Journal: Clinical drug investigation 20120701
Title: Drug-induced hypoglycaemia in type 2 diabetes.
Journal: Expert opinion on drug safety 20120701
Title: Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.
Journal: Diabetes, obesity & metabolism 20120601
Title: An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Journal: Current diabetes reviews 20120501
Title: Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
Journal: Diabetes, obesity & metabolism 20120401
Title: DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Journal: Diabetes & metabolism 20120401
Title: Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Journal: Current medical research and opinion 20120401
Title: Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Journal: Diabetes technology & therapeutics 20120401
Title: Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315
Title: Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.
Journal: Diabetes/metabolism research and reviews 20120301
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Journal: Annals of medicine 20120301
Title: Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
Journal: Clinical drug investigation 20120301
Title: Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Journal: Expert opinion on drug metabolism & toxicology 20120301
Title: Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Journal: Drugs 20120122
Title: The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
Journal: Diabetes technology & therapeutics 20120101
Title: Metformin + saxagliptin for type 2 diabetes.
Journal: Expert opinion on pharmacotherapy 20120101
Title: A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.
Journal: Journal of clinical pharmacology 20120101
Title: Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.
Journal: Cardiovascular diabetology 20120101
Title: A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
Journal: Pharmacoepidemiology and drug safety 20120101
Title: Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Journal: BMC pharmacology 20120101
Title: Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.
Journal: Revista da Associacao Medica Brasileira (1992) 20120101
Title: Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.
Journal: The Journal of organic chemistry 20111216
Title: Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Journal: International journal of clinical practice 20111201
Title: [Incretin-based therapy for treating patients with type 2 diabetes].
Journal: Orvosi hetilap 20111127
Title: Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.
Journal: Diabetes research and clinical practice 20111101
Title: The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Journal: American heart journal 20111101
Title: [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Journal: Orvosi hetilap 20110911
Title: Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20110901
Title: Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
Journal: Annales d'endocrinologie 20110901
Title: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.
Journal: The American journal of cardiology 20110802
Title: Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
Journal: Clinical therapeutics 20110801
Title: Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
Journal: Diabetes, obesity & metabolism 20110701
Title: Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Journal: British journal of clinical pharmacology 20110701
Title: Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Journal: Postgraduate medicine 20110701
Title: Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Journal: Diabetes, obesity & metabolism 20110601
Title: Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Journal: Diabetes, obesity & metabolism 20110601
Title: Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
Journal: Southern medical journal 20110601
Title: Recent diabetes issues affecting the primary care clinician.
Journal: Southern medical journal 20110601
Title: Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (α-N-protected)-L-ornithine using a transaminase or an amine oxidase.
Journal: Enzyme and microbial technology 20110506
Title: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Journal: Contemporary clinical trials 20110501
Title: DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Journal: Diabetes care 20110501
Title: Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.
Journal: Current medical research and opinion 20110401
Title: Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Journal: Clinical pharmacokinetics 20110401
Title: FDA's first active medical product surveillance eyes antidiabetic-MI link.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401
Title: Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Journal: Diabetes & vascular disease research 20110401
Title: Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.
Journal: Diabetes & vascular disease research 20110401
Title: Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics 20110321
Title: Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Journal: Hospital practice (1995) 20110201
Title: Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.
Journal: Prescrire international 20110201
Title: Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Journal: Postgraduate medicine 20110101
Title: Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.
Journal: Journal of atherosclerosis and thrombosis 20110101
Title: Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Journal: Clinical drug investigation 20110101
Title: DPP-4 inhibitors: what may be the clinical differentiators?
Journal: Diabetes research and clinical practice 20101101
Title: Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Journal: International journal of clinical practice 20101101
Title: Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.
Journal: Journal of clinical pharmacology 20101001
Title: Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.
Journal: Current medical research and opinion 20101001
Title: Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Journal: Diabetes/metabolism research and reviews 20101001
Title: Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100915
Title: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Journal: Clinical pharmacokinetics 20100901
Title: Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Patient education and self-management.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Introduction.
Journal: The Journal of family practice 20100901
Title: Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Journal: The Journal of family practice 20100901
Title: [Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes].
Journal: Revue medicale de Liege 20100901
Title: Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Journal: The American journal of the medical sciences 20100801
Title: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Journal: Diabetes, obesity & metabolism 20100801
Title: Saxagliptin efficacy.
Journal: Diabetes, obesity & metabolism 20100801
Title: Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Journal: The American journal of managed care 20100801
Title: Saxagliptin: a new drug for the treatment of type 2 diabetes.
Journal: Mini reviews in medicinal chemistry 20100701
Title: Incretin physiology and its role in type 2 diabetes mellitus.
Journal: The Journal of the American Osteopathic Association 20100701
Title: Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Journal: The Annals of pharmacotherapy 20100601
Title: A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Journal: Postgraduate medicine 20100501
Title: Choosing among the incretin agents and why it matters.
Journal: The Journal of family practice 20100501
Title: [New hypoglycemic agents in type 2 diabetes].
Journal: La Revue du praticien 20100420
Title: [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Journal: Pharmazie in unserer Zeit 20100301
Title: The physiologic role of incretin hormones: clinical applications.
Journal: The Journal of the American Osteopathic Association 20100301
Title: Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.
Journal: ChemMedChem 20100201
Title: Saxagliptin in type 2 diabetes.
Journal: Drugs of today (Barcelona, Spain : 1998) 20100201
Title: Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
Journal: Postgraduate medicine 20100101
Title: Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Journal: Cardiology in review 20100101
Title: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
Journal: The Journal of clinical endocrinology and metabolism 20091201
Title: Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Journal: Expert opinion on pharmacotherapy 20091201
Title: Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Journal: Cleveland Clinic journal of medicine 20091201
Title: Saxagliptin (Onglyza) for type 2 diabetes.
Journal: The Medical letter on drugs and therapeutics 20091102
Title: DPP-4 inhibitors in clinical practice.
Journal: Postgraduate medicine 20091101
Title: Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.
Journal: Current medical research and opinion 20091001
Title: Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.
Journal: Journal of managed care pharmacy : JMCP 20091001
Title: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.
Journal: Diabetes care 20090901
Title: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.
Journal: International journal of clinical practice 20090901
Title: FDA approves saxagliptin for type 2 diabetes.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090901
Title: Defining the importance of daily glycemic control and implications for type 2 diabetes management.
Journal: Postgraduate medicine 20090901
Title: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
Journal: Best practice & research. Clinical endocrinology & metabolism 20090801
Title: Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090601
Title: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Journal: Diabetes, obesity & metabolism 20090601
Title: Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal: Advances in therapy 20090501
Title: DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
Journal: Advances in therapy 20090301
Title: Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Advances in therapy 20090301
Title: New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
Journal: The Diabetes educator 20090101
Title: Prasugrel hydrochloride, dronedarone, and saxagliptin hydrochloride.
Journal: Journal of the American Pharmacists Association : JAPhA 20090101
Title: Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal: IDrugs : the investigational drugs journal 20081201
Title: Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
Journal: Diabetes, obesity & metabolism 20080501
Title: Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation.
Journal: Protein science : a publication of the Protein Society 20080201
Title: DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Journal: International journal of clinical practice 20061101
Title: Biocatalytic ammonolysis of (5S)-4,5-dihydro-1H-pyrrole-1,5-dicarboxylic acid, 1-(1,1-dimethylethyl)-5-ethyl ester: preparation of an intermediate to the dipeptidyl peptidase IV inhibitor Saxagliptin.
Journal: Bioorganic & medicinal chemistry letters 20060201
Title: Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118).
Journal: Archives of biochemistry and biophysics 20060101
Title: Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Journal: Journal of medicinal chemistry 20050728
